Treatment of Hypertension With Adalat® in Combination With Other Drugs

Completed

• Conditions: Hypertension
• Interventions: Drug: Nifedipine (Adalat, BAYA1040)

• Registration Number: NCT01118286
• Lead Sponsor: Bayer

Brief Summary

To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2010-05-05
• Study First Submitted QC: 2010-05-05
• Study First Posted: 2010-05-06
• Study Completion: 2011-09
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-26
• Last Update Posted: 2012-06-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 4497

Inclusion Criteria

• Previously untreated hypertensive patients starting with combination therapy containing nifedipine or
• Insufficiently controlled hypertensive pts. receiving nifedipine as an add-on to existing non-CCB (calcium-channel-blocker) containing antihypertensive therapy

Exclusion Criteria

• None. Exclusion criteria are defined by contraindications and precautions as stated in the local product information.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 1	Nifedipine (Adalat, BAYA1040)	-

Primary Outcome Measures

Name	Time	Method
Evaluation of treatment success (lowering of blood pressure in mmHg) in adult hypertensive patients	After three months